Cara Therapeutics Inc (CARA)

Jun 13, 2025

Cara Therapeutics (NASDAQ:TVRD) Now Covered by Analysts at Piper Sandler - Defense World

Jun 13, 2025

Jun 12, 2025

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga

Jun 12, 2025

Jun 12, 2025

Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler - MarketBeat

Jun 12, 2025

Jun 12, 2025

Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - marketscreener.com

Jun 12, 2025

Jun 12, 2025

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia

Jun 12, 2025

Jun 12, 2025

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com Canada

Jun 12, 2025

Jun 11, 2025

How To Trade (CARA) - news.stocktradersdaily.com

Jun 11, 2025

Jun 09, 2025

Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks

Jun 09, 2025

May 29, 2025

Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages - Defense World

May 29, 2025

May 29, 2025

Oppenheimer Begins Coverage on Cara Therapeutics (NASDAQ:TVRD) - MarketBeat

May 29, 2025

May 28, 2025

BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa

May 28, 2025

May 28, 2025

BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com

May 28, 2025

May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com

May 27, 2025

May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com

May 27, 2025

May 27, 2025

Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks

May 27, 2025

May 26, 2025

Cara Therapeutics (NASDAQ:TVRD) Raised to “Hold” at Wall Street Zen - Defense World

May 26, 2025

May 21, 2025

TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa

May 21, 2025

May 21, 2025

TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com

May 21, 2025

May 21, 2025

Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com

May 21, 2025

May 21, 2025

Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India

May 21, 2025

May 16, 2025

Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World

May 16, 2025

May 15, 2025

BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com UK

May 15, 2025

May 14, 2025

Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN

May 14, 2025

May 14, 2025

Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter

May 14, 2025

May 13, 2025

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire

May 13, 2025

May 08, 2025

Where are the Opportunities in (CARA) - news.stocktradersdaily.com

May 08, 2025

May 06, 2025

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire

May 06, 2025

May 04, 2025

Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Average Rating of “Hold” from Brokerages - Defense World

May 04, 2025

May 02, 2025

Cara Therapeutics (NASDAQ:CARA) Coverage Initiated at StockNews.com - Defense World

May 02, 2025

May 01, 2025

Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock By Investing.com - Investing.com Canada

May 01, 2025

Apr 30, 2025

Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock - Investing.com

Apr 30, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Apr 24, 2025

What's Going On With Cara Therapeutics Stock? - MSN

Apr 24, 2025

Apr 23, 2025

(CARA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Apr 23, 2025

Apr 23, 2025

Form 8-KCurrent report - ADVFN

Apr 23, 2025

Apr 17, 2025

TVRD stock soars to 52-week high, reaching $19.01 - Investing.com Australia

Apr 17, 2025

Apr 16, 2025

Tvardi Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq

Apr 16, 2025

Apr 15, 2025

Tvardi Therapeutics Closes Merger with Cara Therapeutics - citybiz

Apr 15, 2025

Apr 15, 2025

Cara Therapeutics Inc Stock Price, Quotes and Forecasts - Benzinga

Apr 15, 2025

Apr 15, 2025

Cara Therapeutics Completes Merger with Tvardi Therapeutics - TipRanks

Apr 15, 2025

Apr 15, 2025

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewswire

Apr 15, 2025

Apr 15, 2025

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - Benzinga

Apr 15, 2025

Apr 15, 2025

Cara Therapeutics announces 1-for-3 reverse stock split related to Tvardi merger - Hartford Business Journal

Apr 15, 2025

Apr 14, 2025

Cara Therapeutics (CARA) to Rebrand and Trade as Tvardi Therapeu - GuruFocus

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics Announces 1-for-3 Reverse Stock Split - citybiz

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com - Investing.com South Africa

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics Announces 1-For-3 Reverse Stock Split - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Cara Approves Reverse Split in Connection With Tvardi Merger - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics announces 1-for-3 reverse stock split - Investing.com

Apr 14, 2025